Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

Hilf, Norbert; Kuttruff-Coqui, Sabrina; Frenzel, Katrin; Bukur, Valesca; Stevanović, Stefan; Gouttefangeas, Cécile; Platten, Michael; Tabatabai, Ghazaleh; Dutoit, Valérie; Burg, Sjoerd H. van der; Straten, Per thor; Martínez‐Ricarte, Francisco; Ponsati, Berta; Okada, Hideho; Lassen, Ulrik; Admon, Arie; Ottensmeier, Christian; Ulges, Alexander; Kreiter, Sebastian; Deimling, Andreas von; Skardelly, Marco; Migliorini, Denis; Kroep, Judith R.; Idorn, Manja; Rodón, Jordi; Piró, Jordi; Poulsen, Hans Skovgaard; Shraibman, Bracha; McCann, Katy J.; Mendrzyk, Regina; Löwer, Martin; Stieglbauer, Monika; Britten, Cedrik M.; Capper, David; Welters, Marij J.P.; Sahuquillo, Juan; Kiesel, Katharina; Derhovanessian, Evelyna; Rusch, Elisa; Bunse, Lukas; Song, Colette; Heesch, Sandra; Wagner, Claudia; Kemmer-Brück, Alexandra; Ludwig, Jörg; Castle, John C.; Schoor, Oliver; Tadmor, Arbel D.; Green, Edward; Fritsche, Jens; Meyer, Miriam; Pawlowski, Nina N.; Dorner, Sonja; Hoffgaard, Franziska; Rössler, Bernhard; Maurer, Dominik; Weinschenk, Toni; Reinhardt, Carsten; Huber, Christoph; Rammensee, Hans Georg; Singh‐Jasuja, Harpreet; Şahin, Uğur; Dietrich, Pierre Yves; Wick, Wolfgang

doi:10.1038/s41586-019-0959-z

Cited by 13 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the help of such methodologies, researchers can prioritise within a list of potential targets. Four cancer vaccine studies targeting cancer mutanome to treat advanced melanoma and newly diagnosed glioblastoma have been reported recently [ 72 , 112 , 113 , 114 ] (NCT02149225, NCT01970358, NCT02035956, NCT02287428). In HNSCCs, Transgene (France) initiated a randomised Phase 1 clinical trial of TG4050, in which an MVA vaccine encoding multiple neoepitopes is made for each patient (NCT04183166, Table 2 ).…”

Section: Non-viral Antigensmentioning

confidence: 99%

HNSCC: Tumour Antigens and Their Targeting by Immunotherapy

Witzleben

Wang

Laban

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of malignant tumours typically caused by alcohol and tobacco consumption, although an increasing number of HNSCC arise due to persistent infection with high-risk human papilloma virus (HPV). The treatment of HNSCC remains challenging, and the first-line setting is focused on surgery and chemoradiotherapy. A substantial proportion of HNSCC patients die from their disease, especially those with recurrent and metastatic disease. Among factors linked with good outcome, immune cell infiltration appears to have a major role. HPV-driven HNSCC are often T-cell rich, reflecting the presence of HPV antigens that are immunogenic. Tumour-associated antigens that are shared between patients or that are unique to an individual person may also induce varying degrees of immune response; studying these is important for the understanding of the interaction between the host immune system and the cancer. The resulting knowledge is critical for the design of better immunotherapies. Key questions are: Which antigens lead to an adaptive immune response in the tumour? Which of these are exploitable for immunotherapy? Here, we review the current thinking regarding tumour antigens in HNSCC and what has been learned from early phase clinical trials.

show abstract

Section: Non-viral Antigensmentioning

confidence: 99%

HNSCC: Tumour Antigens and Their Targeting by Immunotherapy

Witzleben

Wang

Laban

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…High resolution mass spectrometric-based proteomics techniques are used for the detection of serum monoclonal antibodies [16]. High-end mass spectrometers with different fragmentation techniques, such as front-end and electron transfer dissociation and ultraviolet photodissociation (UVPD), can be used to increase the mass detection range and protein sequence coverage of antibodies [30] and open ways to identify specific antibodies present in serum or other biofluids.…”

Section: Ms Methods and Techniquesmentioning

confidence: 99%

“…Nejo and coworkers [1] describe the results of a GAPVAC-101 clinical trial suggesting that it may be possible to combine both non-mutant antigen and neoantigen targets to elicit potential immune responses against heterogeneous glioma antigens [15]. The 'off-the-shelf' non-mutant peptide warehouse system is useful because it allows multiple personalized selection of antigen peptides that have been validated for their immunogenicity and HLA presentation [16,17]. The non-mutant antigen ephrin type-A receptor 2 (EphA2), for instance, has been observed to be generally negative in normal glial cells, and be overexpressed in approximately 90% of glioblastoma (GBM) samples [18].…”

Section: Neoantigensmentioning

confidence: 99%

Using phosphoproteomics and next generation sequencing to discover novel therapeutic targets in patient antibodies

Zeneyedpour

Hoff

Luider

2020

Expert Review of Proteomics

View full text Add to dashboard Cite

show abstract

“…Meanwhile, CD4+ T cell activation has evolved as an essential goal of cancer vaccines, whereby two main strategies are used. The first relies on the use of synthetic peptides, either as a mixture of exact MHC-class I and -class II ligands [124,125], or (overlapping) synthetic long peptides (SLPs) [126][127][128][129]. The second approach uses nucleic acids (DNA or RNA) encoding for the relevant antigens or fragments thereof.…”

Section: Targeting Cd4+ T Cells With Vaccinesmentioning

confidence: 99%

CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy

Richardson

Schöllhorn

Gouttefangeas

et al. 2021

Cancers

View full text Add to dashboard Cite

Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention in the field, as they are not only essential to promote help to CD8+ T cells, but are also able to kill tumor cells directly (via MHC-class II dependent recognition) or indirectly (e.g., via the activation of other immune cells like macrophages). Therefore, immunotherapy approaches have shifted from only stimulating CD8+ T cells to targeting and assessing both, CD4+ and CD8+ T cell subsets. Here, we discuss the various subsets of CD4+ T cells, their plasticity and functionality, their relevance in the antitumor immune response in patients affected by cancer, and their ever-growing role in therapeutic approaches for human cancer.

show abstract

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

Cited by 13 publications

References 0 publications

HNSCC: Tumour Antigens and Their Targeting by Immunotherapy

HNSCC: Tumour Antigens and Their Targeting by Immunotherapy

Using phosphoproteomics and next generation sequencing to discover novel therapeutic targets in patient antibodies

CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy

Contact Info

Product

Resources

About